Carotid intima media thickness is associated with plasma lipoprotein‐associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes

BACKGROUND A recent meta-analysis showed that both plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2) ) mass and activity independently predict cardiovascular events. Notably, Lp-PLA(2) activity but not mass was found to be a determinant of cardiovascular outcome in type 2 diabetes mellitus. We questioned whether relationships of carotid intima media thickness (IMT), a measure of subclinical atherosclerosis, with Lp-PLA(2) mass differ between diabetic and nondiabetic subjects. MATERIALS AND METHODS Relationships of IMT with plasma Lp-PLA(2) mass (turbidimetric immunoassay) were compared in 74 patients with type 2 diabetes and in 64 nondiabetic subjects. RESULTS IMT was increased (P=0·016), but plasma Lp-PLA(2) mass was decreased in patients with diabetes compared to nondiabetic subjects (277±66 vs. 327±62μgL(-1) , P<0·001). In nondiabetic subjects, IMT was correlated positively with Lp-PLA(2) (r=0·325, P<0·009); multiple linear regression analysis confirmed an independent association of IMT with Lp-PLA(2) (ß=0·192, P=0·048). In contrast, IMT was unrelated to Lp-PLA(2) in patients with diabetes (r=0·021, P=0·86), and the relationship of IMT with Lp-PLA(2) was different in diabetic and control subjects (P<0·001). The relationship of Lp-PLA(2) with the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio also differed between diabetic and nondiabetic subjects (P<0·001). CONCLUSIONS Plasma Lp-PLA(2) may relate to early stages of atherosclerosis development. In diabetes mellitus, in contrast, the association of IMT with plasma Lp-PLA(2) mass is abolished, which could be partly ascribed to redistribution of Lp-PLA(2) mass from apolipoprotein B-containing lipoproteins towards HDL. These findings raise questions about the usefulness of plasma Lp-PLA(2) mass measurement as a marker of subclinical atherosclerosis in type 2 diabetes mellitus.

[1]  E. C. van Winden,et al.  Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages , 2010, Journal of Lipid Research.

[2]  A. Marciniak,et al.  The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. , 2010, Life sciences.

[3]  Jackie A Cooper,et al.  PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry , 2010, Circulation.

[4]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[5]  E. Rimm,et al.  Lipoprotein-Associated Phospholipase A2 Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 Diabetes , 2010, Diabetes.

[6]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[7]  A. Tselepis,et al.  The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. , 2009, Biochimica et biophysica acta.

[8]  W. Sluiter,et al.  High plasma C‐reactive protein (CRP) is related to low paraoxonase‐I (PON‐I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus , 2009, Clinical endocrinology.

[9]  M. Gomes,et al.  Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes. , 2008, Prostaglandins & other lipid mediators.

[10]  A. Khera,et al.  Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. , 2008, Clinical chemistry.

[11]  Qingbo Xu,et al.  Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. , 2008, European heart journal.

[12]  G. Berglund,et al.  Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden. , 2008, Atherosclerosis.

[13]  G. Berglund,et al.  Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  G. Berglund,et al.  The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. , 2007, Atherosclerosis.

[15]  S. Humphries,et al.  Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. , 2006, Atherosclerosis.

[16]  P. Raskin,et al.  The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. , 2006, Journal of diabetes and its complications.

[17]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary Atherosclerosis: The Rotterdam Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  C. Packard,et al.  Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke , 2005, Nature Clinical Practice Cardiovascular Medicine.

[19]  M. Argyropoulou,et al.  Lack of Association Between Carotid Intima-Media Thickness and PAF-Acetylhydrolase Mass and Activity in Patients with Primary Hyperlipidemia , 2005, Angiology.

[20]  D. Jacobs,et al.  Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Nagano,et al.  Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus Published, JLR Papers in Press, July 16, 2003. DOI 10.1194/jlr.D300021-JLR200 , 2003, Journal of Lipid Research.

[22]  B. Duncan,et al.  Diabesity: An Inflammatory Metabolic Condition , 2003, Clinical chemistry and laboratory medicine.

[23]  J. Azuma,et al.  Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. , 2003, Diabetes research and clinical practice.

[24]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[25]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[26]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[27]  R H Selzer,et al.  Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. , 1994, Atherosclerosis.

[28]  W. Sluiter,et al.  Alimentary lipemia-induced redistribution of cholesteryl ester between lipoproteins. Studies in normolipidemic, combined hyperlipidemic, and hypercholesterolemic men. , 1989, Arteriosclerosis.

[29]  Yuling Hong,et al.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis. , 2011, North American journal of medicine & science.

[30]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[31]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .